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Abstract
Herpesvirus of turkey (HVT) is being widely used as a vector for development of recombinant vaccines and US2 and US10
genes are often chosen as insertion sites for targeted gene expression. However, the different effects of the two genes for
generation of recombinant HVT vaccines were unknown. In order to compare the effects of inserted genes in the two sites
on the efficacy of the recombinant vaccines, host-protective haemagglutinin (HA) gene of the highly pathogenic avian
influenza virus (HPAIV) H5N1 was inserted into either US2 or US10 gene locus of the HVT. The resulting US2 (rHVT-US2-HA)
or US10 (rHVT-US10-HA) recombinant HVT viruses were used to infect chicken embryo fibroblasts. Plaques and the growth
kinetics of rHVT-US2-HA-infected chicken embryo fibroblasts were similar to those of parental HVT whereas rHVT-US10-HA
infected chicken embryo fibroblasts had different growth kinetics and plaque formation. The viremia levels in rHVT-US10-HA
virus-infected chickens were significantly lower than those of rHVT-US2-HA group on 28 days post infection. The vaccine
efficacy of the two recombinant viruses against H5N1 HPAIV and virulent Marek’s disease virus was also evaluated in 1-day-
old vaccinated chickens. rHVT-US2-HA-vaccinated chickens were better protected with reduced mortality than rHVT-US10-
HA-vaccinated animals following HPAIV challenge. Furthermore, the overall hemaglutination inhibition antibody titers of
rHVT-US2-HA-vaccinated chickens were higher than those of rHVT-US10-HA-vaccinated chickens. Protection levels against
Marek’s disease virus challenge following vaccination with either rHVT-US2-HA or rHVT-US10-HA, however, were similar to
those of the parental HVT virus. These results, for the first time, indicate that US2 gene provides a favorable foreign gene
insertion site for generation of recombinant HVT vaccines.
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Introduction
Herpesvirus of turkey (HVT) is a naturally occurring, non-
pathogenic alphaherpesvirus originally isolated from domestic turkeys
in the late of 1960s [1]. HVT is a member of the genus Mardivirus and is
antigenically and genetically related to Marek’s disease (MD) virus
(MDV), the etiologic agent of the globally and economically significant
Marek’s disease in chickens [2,3]. MDV is a chicken pathogen that
results in the development of T-cell lymphomas and mononuclear
infiltration of peripheral nerves in a matter of weeks following infection
[2]. Since antigenic similarities between MDV and HVT have been
documented, these similarities have been exploited in the context of
vaccination strategies,that is, HVT vaccination of chickens has resulted
in long-lasting, protective immunity against MD [4,5]. Since the early
1970s chicken vaccinations with HVT have dramatically reduced MD-
related losses [6].
HVT not only serves as a viable vaccine option for prevention
of MD but can also be used as a vector for development of
recombinant vaccines. Specifically, HVT provides an efficient
delivery system for immunogenic genes that can facilitate the
control of multiple poultry-related diseases. HVT possesses some
ideal characteristics: (1) HVT is a herpesvirus that infects chickens
persistently, resulting in continuous immune system stimulation
that helps maintain protective antibody levels elevated, (2) HVT
vaccine is also available in a cell-free ‘dry’ (lyophilized) form that is
convenient for long-term storage and transport [7,8] and (3) MDV
genome is large enough to accommodate multiple foreign genes.
Recombinant HVT (rHVT) vaccine has been proven to be one of
useful viral vectors of targeted gene expression and developed for
the prevention of diseases caused by infections with various fowl
disease-associated viruses [7,9–13].
Some genes in some alphaherpesviruses have been reported as
‘nonessential’ for viral growth in cell culture, but ‘nonessential’
genes can be used in the context of specific in vitro systems and
do not necessarily suggest that a respective gene product is
nonessential in all in vitro or in vivo models. Nevertheless,
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for design of alphaherpesvirus vectors [1,10]. In the context of the
herpesvirus genome, the unique short (US) 1, US2, US10 and
thymidine kinase genes have been defined as ‘nonessential’ for
growth in cell cultures [11,14,15] and the US2 and US10 genes
have been used as insertion sites for foreign genes in development
of recombinant HVT or MDV. For example, when a recombinant
CVI-988 (rCVI-988) expressing infectious bursal disease virus
(IBDV) VP2 at the US2 site was engineered, vaccination with this
recombinant vaccine conferred partial protection against virulent
IBDV (.55%) and full protection against vvMDV challenge [16].
Baigent et al. constructed a full-length infectious bacterial artificial
chromosome (BAC) clone consisting of HVT (HVT-BAC)
following insertion into the US2 locus and these HVT-BAC
clones conferred 100% protection against vMDV challenge [1]. In
addition, rHVT expressing Newcastle disease virus (NDV) fusion
protein (F) at the US10 site conferred 90% protection against
velogenic NDV and effective protection against vvMDV in various
studies [10,17]. In these studies US2 and US10 gene loci were
often chosen as insertion sites and the results demonstrated that
insertion of foreign genes into the US2 and US10 gene loci did not
impair recombinant virus replication rates in vivo [10,18,19].
Although US2 and US10 genes have been used in turn as insertion
sites for generating vaccines against the same or various diseases,
the different effects of the two genes for the generation of rHVT
vaccines were unknown. Therefore, our goal was to find which
gene, US2 or US10, would be a more suitable insertion site for
foreign genes in the development of recombinant alphaherpesvirus
vaccines.
Avian influenza (AI) is a highly contagious, re-emerging
infectious disease affecting poultry worldwide. Highly pathogenic
avian influenza (HPAI) viruses (HPAIV) are comprised of a
particular avian influenza virus (AIV) subtype H5 and H7 by the
World Organization for Animal Health (OIE) [20]. Conventional
inactivated vaccines have been considered to be effective in the
control and prevention of avian influenza outbreaks but the
difficulty in differentiating infected birds from vaccinated ones
limits their use [21]. The basis of protective humoral responses is
contingent on the development of neutralizing antibodies against
the haemagglutinin protein and a variety of vaccines under
development derived from the AIV HA gene product, including
recombinant virus vaccines and DNA vaccines, have shown
effective protection against challenge with homologous strains
[22–25].
In this study, we describe construction of two rHVT viruses
expressing the AIV H5 HA gene at the US2 and US10 sites,
respectively. The abilities of the rHVTs to replicate in vitro and vivo
and elicit protective immunity in chickens following challenge with
either AIV or MDV were assessed. We demonstrated that the
HVT-based recombinant vaccine expressing the AIV HA gene at
the US2 site conferred more effective protection against challenge
with AIV when compared to protection conferred by rHVT
expressing the AIV HA gene at the US10 site.
Results
Construction and purification of recombinant viruses
rHVT viruses expressing the AIV H5 gene at either US2 or
US10 site were generated by constructing two recombinant
plasmids following a series of functional fragment insertions
containing the left-and right-side homologies of US2 or US10 gene
in addition to both the Eco-gpt cassette (for selection purposes) and
the HA cassette. Transfection of chicken embryo fibroblasts
(CEFs) with wild-type HVT (wtHVT) DNA together with pGAB-
gpt-HA or pUAB-gpt-HA, respectively, resulted in viral replication
demonstrating the viability of the respective recombinant viruses.
After eight rounds of selection process in selection medium,
purified rHVT-US2-HA and rHVT-US10-HA recombinants
were obtained, respectively.
Southern blotting hybridization
A major 16 kb fragment from the BamHI-digested rHVT-US2-
HA DNA and another major 20 kb fragment from the BamHI-
digested rHVT-US10-HA DNA were detected with HA probe by
Southern blotting hybridization, respectively, indicating that the
transfer vectors were correctly inserted in the US2 region or the
US10 region. We also carried out Southern hybridization to
confirm the existence of gB from the wtHVT and recombinant
viruses. As expected, a single band of the predicted size of about
25 kb was detected in DNA extracted from rHVT-US2-HA or
rHVT-US10-HA-infected cells. A similar-size band was also
detected in the DNA samples extracted from wtHVT-infected
cells (Figure 1).
Immunofluorescence staining and Western blot analysis
CEFs were infected with either rHVT-US2-HA, rHVT-US10-
HA or wtHVT virus. HA expression was detected by immuno-
fluorescence staining using chicken anti-H5 serum and fluorescein
isothiocyanate (FITC)-labeled rabbit anti-chicken IgG. Fluores-
cence was detected in recombinant virus-infected cells following
microscopic analysis in contrast to cells infected with wtHVT
(Figure 2). These results indicated that rHVT-US2-HA and
rHVT-US10-HA were successfully expressed in CEFs.
Three bands were detected by Western blot analysis using
chicken anti-H5 AIV HA serum and IR dye 800-labeled rabbit
anti-chicken IgY in lysates of cells infected with rHVT-US2-HA or
rHVT-US10-HA after incomplete treatment with trypsin, which
represented the intact HA precursor HA0, the cleaved products
HA1 and HA2. As expected, HA specific band was not detected in
CEFs infected with wtHVT (Figure 3).
Haemagglutination assay
Haemagglutination assays using 0.5% chicken red blood cells
demonstrated that the HA antigen produced on each of the two
recombinant viruses agglutinated chicken red blood cells in
contrast to wtHVT. The haemagglutination titers of rHVT-
US2-HA, rHVT-US10-HA and wtHVT were 3log2, 2log2 and 0,
respectively.
Figure 1. Southern blotting hybridization of BamHI-digested
DNA extracted from cells infected with rHVT-US2-HA, rHVT-
US10-HA or wtHVT virus. HA specific band was detected with HA
probe in the DNA from rHVT-US2-HA (Lane 2) or rHVT-US10-HA (Lane 3).
In contrast, no band was dectected in the DNA from wtHVT (Lane 1).
With gB probe, DNA of cells infected with rHVT-US2-HA, rHVT-US10-HA
or wtHVT virus all contained gB specific band (Lane 4–6).
doi:10.1371/journal.pone.0022549.g001
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After recombinant viruses were confirmed to express HA, we
determined whether the growth curves of the US2 and US10
gene-deleted recombinant viruses were comparable to that of
wtHVT. This was carried out three times by infecting CEFs with
100 plaque forming units (p.f.u.) of either wtHVT or one of the
two recombinant viruses and assessing plaque formation at 0, 24,
36, 48, 54, 72, 96 and 120 h post infection.
Plaque morphology and sizes of wtHVT and rHVT-US2-HA
virus infected CEFs were indistinguishable from each other at 96 h
post infection, and rHVT-US2-HA viruses had very similar in vitro
replication kinetics to wtHVT. However, extensive syncytia were
formed in HVT-US10-HA infected cells and it replicated at a
higher rate than wtHVT between 48–54 h post infection and grew
slowly 54 h post infection (Figure 4).
Viremia levels of chickens infected with HVT-US2-HA or
HVT-US10-HA
The viremia levels in five birds from each group were
determined on 7, 14, 21, 28 days post infection. As indicated in
Figure 5, the viremia levels in rHVT-US10-HA virus-infected
chickens were slightly lower than those of rHVT-US2-HA group
on 14 and 21 days post infection, but were significantly lower than
those of rHVT-US2-HA group on 28 days post infection
(P,0.05). The viremia levels were indistinguishable between
wtHVT virus infected chickens and rHVT-US2-HA virus infected
chickens during the whole experimental period.
Evaluation of protection against AIV challenge
To determine the protective efficacy of the recombinant viruses
against challenge with HPAIV, chickens were infected with 10
5
EID50 of HPAIV H5N1 A/Goose/HLJ/QFY/2003 4 weeks post
vaccination. Only 4/15 (26.7%) chickens vaccinated with rHVT-
US10-HA were protected whereas 9/15 (60%) of the chickens
vaccinated with rHVT-US2-HA were protected (Table 1). In
contrast to the vaccine groups, control chickens injected with
wtHVT died within two days post challenge. Furthermore, we
were able to isolate viruses from chickens vaccinated with rHVT-
US2-HA or rHVT-US10-HA on 3 and 5 days post challenge but
virus shedding was undetectable at 1 week post challenge.
HA antibodies constitute one of the major defenses against viral
infections, therefore, we examined the relative capacities of the
rHVT-HA vaccines to elicit protective humoral immune responses
(Table 2). Although chickens vaccinated with either rHVT-US2-
HA or rHVT-US10-HA elicited HA antibody responses 2 weeks
post vaccination, the antibody levels detected were low. However,
haemagglutination inhibition (HI) antibody titers increased 3–4
weeks post vaccination and the increase of mean HI antibody titers
in chickens vaccinated with rHVT-US2-HA was statistically
significant (P,0.05) when compared to chickens vaccinated with
rHVT-US10-HA on 21 and 28 days post challenge. The control
group inoculated with wtHVT showed no evidence of HI antibody
responses.
Evaluation of protection against MDV challenge
The protective efficacy against Marek’s disease of the rHVT
vaccines was determined by assessing cumulative survival rates and
gross/histological lesions in vaccinated animals post challenge with
MDV. Evidence of MD was observed in control animals 4 weeks
post challenge with vMDV strain J-1and 95% of the chickens in
this group developed MD during the 60-day experimental period
(Table 3). Lymphoid tumors were observed in several visceral
organs of the dead chickens, particularly in hearts and kidneys. In
Figure 2. Immunofluorescence staining of cells expressing HA antigen of the highly pathogenic avian influenza virus H5N1 in
turkey herpesvirus. Confluent CEFs were infected with either (A) rHVT-US2-HA, (B) rHVT-US10-HA or (C) wtHVT. Cells were incubated with
polyclonal chicken antiserum against HA antigen H5 of avian influenza virus, stained with rabbit anti-chicken IgG-FITC conjugate and then examined
under fluorescence microscopy 48 hours after infection. Magnification 206.
doi:10.1371/journal.pone.0022549.g002
Figure 3. Western blot analysis. CEFs inoculated with recombinant
HVT vaccines were subjected to SDS-PAGE followed by transfer onto a
nitrocellulose membrane. Blots were incubated with chicken anti-HA
antiserum and rabbit anti-chicken IgG conjugate. HA-specific bands
corresponding to the cleaved HA1 and HA2 were detected in
preparations of rHVT-US2-HA or rHVT-US10-HA-infected cells, but not
wtHVT. No staining was observed after incubating blots with conjugate
only (data not shown).
doi:10.1371/journal.pone.0022549.g003
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(Figure 6); 20% of wtHVT and rHVT-US10-HA vaccinated
animals presented with MD (PI value of 78.9) and rHVT-US2-HA
vaccinated animals had an MD incidence rate of 33% (PI value of
65.3). The PI values of the three vaccine groups were not
statistically different (P.0.05).
Figure 4. Plaque morphology and growth rates. CEFs were incubated with either (A) wtHVT, (B) rHVT-US2-HA or (C) rHVT-US10-HA for 96 h and
their respective morphology was assessed. The growth rates of the recombinant and wild-type viral isolates were compared over time (D).
doi:10.1371/journal.pone.0022549.g004
Figure 5. Comparison of viremia levels between rHVT-US2-HA, rHVT-US10-HA or wtHVT. Day old chicks were vaccinated with either
wtHVT, rHVT-US2-HA or rHVT-US10-HA and bled on 7, 14, 21, 28 days post infection for determination of viremia. Stars indicate that the differences
were significant between groups (P,0.05).
doi:10.1371/journal.pone.0022549.g005
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In this study, two recombinant HVTs (rHVT-US2-HA and rHVT-
US10-HA) were generated, and preliminary experiments indicated
that the respective insertions did not affect the rHVT growth in CEFs
as previously described [10,19]. Results from in vitro viral growth curve
analysis demonstrated that replication rates and plaque sizes of rHVT-
US2-HA infected CEFs were similar to those of parental HVT. In
contrast, plaque morphology and replication rates of rHVT-US10-HA
infected CEFs were different to those of wtHVT [10]. Our in vivo
experiments have shown the different growth rates of the recombinant
HVT viruses and wtHVT in chickens by viremia analysis. The viremia
levels in rHVT-US10-HA virus-infected chickens were significantly
lower than those of rHVT-US2-HA group on 28 days post infection
and there was no obvious difference on growth rate between rHVT-
US2-HA and wtHVT group, revealing a similar in vitro growth rate.
However, rHVT-US10-HA replicated at a higher rate than wtHVT
between 48–54 h post vaccination, indicating a different in vivo growth
rate. The viremia levels in rHVT-US10-HA group were lower than
those in rHVT-US2-HA group or wtHVT group during the whole
experimental period.
The virus challenge experiments showed that rHVT-US2-HA
and rHVT-US10-HA vaccinated chickens were 60 and 26.7%
protected against HPAIV challenge and virus shedding data were
consistent with mortality, respectively. Serological data suggested
that rHVT-vaccinated chickens persistently stimulated their host-
immune systems. Chickens vaccinated with rHVT-US2-HA had
significantly higher HI antibody titer levels compared to rHVT-
US10-HA vaccinated chickens on 21 and 28 days post infection.
These results indicated that HVT expressing the HA gene at the
US2 position was significantly more effective in conferring
protective immunity than the virus expressing HA at the US10 site.
Both rHVTs conferred effective protection against vMDV J-1
challenge. rHVT-US10-HA and parental HVT conferred the
same level of protection against MDV challenge (PI value 78.9)
and there were no significant differences between the two groups
whereas protection conferred by rHVT-US2-HA was slightly less
effective (PI value 65.3). These results demonstrated that HA
insertion into either the US2 or US10 gene positions did not
significantly affect the rHVT inducted protection against MDV,
confirming the previous findings [1,10].
When HVT infects CEFs, the cytopathic effect (CPE) was
commonly observed first as round cells and then their fusion
(syncytia) that formed cell foci. The degenerated cells eventually
detached from the dish, producing plaques on the monolayer cell
sheet. Previous studies showed that particular deletion mutations
could alter viral plaque morphology. Mutation in gB gene of HSV-1
caused extensive syncytia formation in infected cells, rather than
rarelycaused cell-cell fusion as previouslyreported [26]. Obvious and
extensive syncytia were formed after CEFs were infected with rHVT-
US10-HA. It is assumed that US10 gene was responsible for plaque
morphology of HVT. In previous MDV/HVT US10 gene relevant
studies, the corruption of this site did not affect plaque morphology,
but all these studies adopted insertion method for interruption and
part of US10 gene could stillbe expressed [10,27]. We replaced HVT
US10 gene with targeted gene in our study, which perhaps can
explain why we obtained different results. Nonetheless, we cannot
ruleout the possibility that HAprotein expression has impact on viral
plaque morphology. Additional studies are currently underway to
define factors involved in mediating these effects.
Previously, recombinant fowlpox virus (rFPV) or Newcastle disease
virus (rNDV) expressing the AIV HA gene were generated and
vaccination data using these recombinant viruses demonstrated that
the rFPV and rNDV conferred significant levels of protection against
Table 1. Protective efficacy of the recombinant vaccines against HPAIV H5 challenge in chickens.
Vaccine formulation
tested Virus isolated from collected swabs (shedding/total [log10 EID50])
a
Day 3 p.c. Day 5 p.c. Survival/total
Oropharyngeal Cloacal Oropharyngeal Cloacal
rHVT-US2-HA 4/13(2.460.7) 1/13(2.860.4) 1/10(2.160.2) 1/10(1.860.3) 9/15
A
rHVT-US10-HA 4/9(2.160.3) 5/9(1.560.5) 3/7(2.860.3) 2/7(2.460.6) 4/15
B
HVT Fc 126 —
b —
b —
b —
b 0/15
aOropharyngeal and cloacal swabs were collected on days 3, 5, and 7 post challenge and titrated in SPF eggs. All control group chickens died before day 7. No virus was
detected in the vaccinated chickens. For this reason day 7 data are excluded.
bAll chickens in this group died before day 3.
Different uppercase superscript letters indicate a significant difference (P,0.05) between groups on respective rows.
doi:10.1371/journal.pone.0022549.t001
Table 2. Results of haemagglutination inhibition test of chickens vaccinated with recombinant vaccines.
Vaccine formulation tested Log2 HI titer at different days post-vaccination(mean±SD)
71 4 2 1 2 8 3 5
rHVT-US2-HA 0 1.6
A60.5 3.05
A60.61 4.05
A60.69 14.361.11
rHVT-US10-HA 0.3600 . 9
B60.3 2.2
B60.35 3.15
B60.70 13.561.04
HVT Fc 126 ND ND ND ND —
a
ND=not determined.
aNegative control; all died.
Different uppercase superscript letters indicate a significant difference (P,0.05) between groups on respective rows.
doi:10.1371/journal.pone.0022549.t002
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AIV gene was a good candidate for control of avian influenza
[21,25,28–31]. In this study, the two rHVTs conferred only partial
protection against AIV challenge. However, beyond our expectation,
almost 90% of chickens in control group died within 24 h post
challenge and the rest of them died two days post challenge. In
previous studies, the cases like this high mortality of chickens in
control group were rare. Therefore, the reason for the slightly lower
protection levels conferred by the rHVT vaccines was likely due to
either low immunization dose or high dose of challenge with HPAIV,
overwhelming protective immune responses. Most of HVT-vector
based antigen delivery systems have been developed for making
recombinant viral vaccines. Studies on recombinant HVT vaccines
have been attempted to develop as bivalent vaccines against NDV,
IBDV or AIV, besides protection from MDV [7,9,10,16]. Remark-
ably, the resulting vaccine Vaxxitek
R HVT+IBD was licensed and
commercialized as an animal herpesvirus vector based product.
Therefore, HVT-vector is a good potential candidate for vaccine
development. However, current MDV vaccines including HVT
cannot stop viral replication and shedding in chicken although they
can protect against tumour formation and hence mortality [1]. The
continued evolution of field viruses towards pathotypes of greater
virulence is attributed to the selection pressures imposed on these
virulent viruses in vaccinated chicken. Therefore, HVT vaccine may
not effectively protect against MDV in the future.
Our study, for the first time, describes different effects of US2
and US10 insertion sites in the development of recombinant
HVTs and the US2 gene locus as an insertion site for the
expression of vaccine targets is more effective than US10 site in
construction of an rHVT vaccine for use in chickens.
Materials and Methods
Ethics Statement
Animal experiments were approved by Harbin Veterinary
Research Institute of the Chinese Academy of Agricultural
Sciences and performed in accordance with animal ethics
guidelines and approved protocols. The Animal Ethics Committee
approval number was Heilongjiang-SYXK 2006-032.
Viruses and cells
The wtHVT FC126 strain (twelfth duck embryo fibroblast
passage stock) was used for construction of the recombinant
viruses. MDV strain J-1 is a reference virulent MDV strain isolated
from Beijing district in China [32] and is a standard virulent
reference challenge strain in MDV research (tenth duck embryo
fibroblast passage stock) [33,34]. Both viral strains were obtained
from the Avian Infectious Diseases Laboratory of the Harbin
Veterinary Research Institute of the Chinese Academy of
Agricultural Sciences and were propagated in primary CEFs
prepared from 10-day-old, specific-pathogen-free embryos.
HPAIV H5N1 virus A/goose/Guangdong/3/96 [35] and A/
Goose/HLJ/QFY/2003 [36] shares approximately 97% identity
in HA gene. They were propagated in the allantoic cavities of 10-
day-old SPF chicken embryonated eggs and then kept at 270uC
before RNA extraction or use in challenge studies.
Figure 6. Characterization of vaccine efficacy. Day old chickens were vaccinated with either wtHVT, rHVT-US2-HA or rHVT-US10-HA and
challenged 14 days later with MDV J-1. Data are expressed as percentage survival of birds from unvaccinated or vaccinated groups.
doi:10.1371/journal.pone.0022549.g006
Table 3. Protective efficacy of recombinant HVTs and wtHVT against MDV challenge.
Vaccine Number of chickens/group MD mortality MD% Protection Index (PI) %
rHVT-US2-HA 15 4 33 65.3
rHVT-US10-HA 15 3 20 78.9
HVT Fc126 15 3 20 78.9
Control 20 11 95 0
MD (%) indicates the percentage of MDV-infected chickens that died after challenge with MDV strain vJ-1 or developed gross tumors prior to experimental termination.
doi:10.1371/journal.pone.0022549.t003
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cDNA corresponding to the A/goose/Guangdong/3/96 HA
open reading frame (1,716 nucleotides) was PCR-amplified using
specific primers (Table 4) that included Kozak consensus
sequences [37]. The PCR products of cDNA HA were digested
with HindIII and SalI and cloned into the pN1-EGFP-derived pN1
vector (deficient in EGFP) (Clontech, Tokyo, Japan). The HA
cassette containing the HCMV immediate-early promoter and the
SV40 poly-adenylation signal were PCR-amplified using primers
containing a PacI restriction site (Table 4).
Construction of the US2 (pGAB-gpt-HA) deletion plasmid
For construction of the US2 gene transfer vector, guanine
phosphoribosyl transferase gene (Eco-gpt) was PCR-amplified from
the pEco-gpt plasmid using primers containing HindIII restriction
enzyme sites (Table 4) and then cloned into pGAB that included 2.0
and 2.7 kilo base pair (kb) fragments flanking the HVT US2 gene to
obtain the pGAB-gpt plasmid [38]. The pEco-gpt plasmid was
constructed in our laboratory, which contained the E. coli selective
gpt marker under the control of the HCMV immediate-early
promoter [36]. The HA cassette was cutusing PacI and inserted into
pGAB-gpt to obtain the transfer plasmid pGAB-gpt-HA.
Construction of the US10 deletion plasmid (pUAB-gpt-
HA)
The US10 gene transfer vector was constructed by PCR-
amplification of two fragments (2.6 kb and 2.6 kb) mapping to
each side of the HVT US10 open reading frame using primers
containing appropriate restriction enzyme sites (Table 4). Both
fragments were subsequently cloned into the pUC119 vector
(TaKaRa, Dalian, China) to generate pUAB. The Eco-gpt gene
was then PCR amplified from the pEco-gpt plasmid using primers
containing NotI restriction site (Table 4) and ligated with pUAB to
obtain the plasmid pUAB-gpt. The HA cassette was then cut by
PacI and inserted into the pUAB-gpt to obtain the recombination
plasmid pUAB-gpt-HA.
Transfection and isolation of HVT recombinants
Recombinant HVT viruses were generated as described
previously [1,38]. Briefly, primary CEFs were co-transfected with
1 mg of each of pGAB-gpt-HA and 5 mg HVT DNA using
liposome [39]. The transfected cells were maintained in selective
medium containing mycophenolic acid (350 mg/ml), xanthine
(70 mg/ml) and hypoxanthine (100 mg/ml), and monitored daily
for CPE. To purify rHVT-US2-HA, virus-containing cells were
passaged in selection medium for eight rounds until no cells with
CPE were observed in selection medium suspensions. The rHVT-
US10-HA virus was obtained by the same method.
Southern blot analysis
Total viral (rHVT-US2-HA, rHVT-US10-HA or wtHVT) DNA
was extracted using the sodium dodecyl sulfate (SDS)-protinase K-
phenol protocol and analysed by restriction digestion with BamHI.
For Southern hybridization, DNA was separated by 1.0% agarose
gel electrophoresis, transferred to membranes and probed with
DIG-labeled probes (Roche Molecular Biochemicals, Mannheim,
Germany) specific for glycoprotein B (gB) and HA according to the
manufacturer’s protocols. The sequences of the primers used to
synthesize the DIG-labeled probes are shown in Table 4.
Indirect immunofluorescence assay (IFA) and Western
blot analysis
Chicken embryo fibroblast monolayers (80–90% confluent)
were infected with rHVT-US2-HA, rHVT-US10-HA or wtHVT
respectively, and then washed 3 times with phosphate buffered
saline (PBS) and fixed with ice-cold ethanol for 15 min following
the appearance of CPE. The wells were overlaid with polyclonal
chicken antibodies produced by vaccination with the H5 AIV HA
gene DNA vaccine (1:100), and incubated at 37uC for 1 h. The
wells were washed 3 times with PBS and incubated with anti-
chicken IgY (IgG) (whole molecule)-FITC antibody produced in
rabbit (1:300) (Sigma, Shanghai, China) at 37uC for 1 h. Wells
were then washed as above, dried and analyzed using an inverted
Table 4. PCR primer sequences used in amplification experiments.
Primer Sequence Target
HA-upper AGGAAGCTTTACCATGGAGAGAATAGTGCTTC HA open reading frame
HA-lower CGGGTCGACTTAAATGCAAATTCTGCATTGTA
HA cassette-upper CGGCGGTTAATTAACGCCATGCATTAGTTATT HA cassette
HA cassette-lower CGG CGG TTAATTAACGCTTACAATTTACGCCT
gpt cassette-upper1 ATTAAGCTTCGCCATGCATTAGTTATTAATAGT gpt cassette with HindIII
gpt cassette-lower1 ATCAAGCTTCGCTTACAATTTACGCCTTAAGAT
US10 left-upper GAGCTCGGGTCCGGGAGGAAGTGA 2.6 kb left region
US10 left-lower GCGGCCGCTAATCAACATATATTGTAT
US10 right-upper TAAGCGGCCGCTTAATTAACATAGGCACGCTCTGATGT 2.6 kb right region
US10 right-lower CGGAAGCTTAGATTAGCAGATTTTCTGG
gpt cassette-upper2 ATTGCGGCCGCCGCCATGCATTAGTTATTAATAGT gpt cassette with NotI
gpt cassette-lower2 ATCGCGGCCGCCGCTTACAATTTACGCCTTAAGAT
HA test-upper ATGGAGAGAATAGTGCTTCTCC HA probe
HA test-lower CAAATTCTGCATTGTAACGAT
gB-upper AGGGAAAGTAGTAGTCGGGGCTGCAGGG gB probe
gB-lower TTCATCATCCGTCTCAGAATCCGTGTCG
doi:10.1371/journal.pone.0022549.t004
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206ELWD objective (Nikon, Tokyo, Japan).
Western blot analysis was carried out as described previously
[40]. Briefly, primary CEFs were infected by PCR-positive
recombinant viruses, respectively, and cells collected when CPE
was detected. Total cell lysates were prepared following incubation
with lysis buffer (10 mM Tris-Cl, pH 7.4, 1 mM MgCl2, 0.5%
NP40, 20 mg/ml DNase I), followed by 0.1% trypsin for 30 min,
subjected to 10% SDS-PAGE and then transferred to nitrocellu-
lose. For HA protein detection, membranes were incubated with
chicken H5-AIV HA specific antiserum (1:100) followed by
detection with IR dye 800-labeled polyclonal rabbit anti-chicken
IgG (Li-Cor, Lincoln, NE, USA) (1:2000) and analyzed using an
Odyssey infrared imager (Li-Cor). Cells infected with wtHVT
were used as negtive control.
Haemagglutination assay
CEFs were infected with rHVT-US2-HA and rHVT-US10-HA,
respectively, and the rHVT expressing AIV H5 HA in the media
concentrated following precipitation with 10% PEG-8000. The
precipitant was resuspended in PBS for the HA assay. Chicken red
blood cells werewashed three times with PBS and resuspended (5%,
v/v) in PBS for use in the HA assay. Haemagglutination tests were
performed in 96-well round-bottom microtiter plates. To determine
whether recombinant viruses possessed chicken red blood cell
haemagglutination properties, 50 ml of concentrated cell superna-
tants and an equal volume of 0.5% chicken red blood cells were
added to each well and the plates incubated for 30 min at 25uC.
Chicken red blood cell suspensions were mixed and allowed to settle
for 30 to 45 min. The HA titers were described as the reciprocal of
the highest virus dilution with 100% HA.
Comparison of in vitro growth rates between wtHVT and
recombinant viruses
The rates of in vitro growth of the viruses on CEFs were studied
by counting the p.f.u. at various time points. For each virus
100 p.f.u. was inoculated onto tissue-culture dishes with 2610
6
CEFs. At various hours post inoculation, virus-infected CEFs were
harvested and serial 10-fold dilutions were added in triplicate onto
the 48-well plates of CEFs. After three days, the titers of the virus
at each time point were calculated from the number of p.f.u. from
each of the dilutions and the growth curves of rHVT-US2-HA,
rHVT-US10-HA and wtHVT determined.
Determination of viremia
One-day-old SPF chicks were assigned to three groups of 20
chickens each and vaccinated intramuscularly with a total of
3000 p.f.u. of either rHVT-US2-HA, rHVT-US10-HA or
wtHVT. After vaccination, five chickens were removed weekly
from each of these groups, and the levels of HVT viremia were
determined for individual chickens as reported previously [10].
Briefly, blood samples in anticoagulants were collected from five
birds of each group and 5 ml blood from each bird was mixed with
5 ml RPMI 1640 medium and 3 ml Histopaque 1077 (Sigma,
Shanghai, China). Samples were centrifuged at 10006 g for
30 min. The leukocytes were recovered and counted. Co-
cultivations were done in duplicate by seeding 2610
6 leukocytes
onto 60-mm plates with CEF monolayers. After 5 days, dishes
were stained with crystal violet and plaques were counted.
AIV challenge experiment
One-day-old chicks were randomly divided into groups of 15 and
vaccinated intramuscularly with atotal of3000 p.f.u. of either rHVT-
US2-HA or rHVT-US10-HA. Another group was inoculated with
wtHVT as a negative control. Day-old chicks were vaccinated only
once and then bled via wing veins weekly for five times. Chick sera
were tested for antibody-mediated haemagglutination inhibition
using the OIE standard method. Four-weeks post vaccination chicks
in each group were challenged intranasally with 0.1 ml of 10
6 ELD50
of highly pathogenic H5N1 A/Goose/HLJ/QFY/2003 virus.
Oropharyngeal and cloacal swabs from respective chickens were
collected on days 3, 5, and 7 post challenge for virus titration and
chickens were observed for disease presentation and mortality.
MDV challenge experiment
A total of 65 1-day-old SPF chicks were vaccinated intramuscularly
with 3000 p.f.u. of either rHVT-US2-HA, rHVT-US10-HA or
wtHVT. Twenty negative control chicks were inoculated with non-
infected CEFs. On 14 days of age birds were challenged intra-
abdominally with 1000 p.f.u. virulent MDV J-1 virus. Mortality during
the course of the experiment was recorded and chickens were
examined for gross MD lesions. On 60 days post challenge, all
surviving birds were euthanized and examined for gross and
histopathological lesions. The percentage of gross MD was calculated
for each test group as the number of chickens with gross MD lesions
divided by number at risk (survivors plus MD deaths)6100 [41].
Vaccinal immunity to MD was expressed as a protective index (PI)
calculated as the percentage of gross MD in non-vaccinated challenged
control chickens minus the percentage of gross MD in vaccinated,
challenged chickens divided by the percentage of gross MD in non-
vaccinated challenged control chickens and multiplied by 100.
Statistical analyses
Comparisons of single treatment among vaccinated groups were
performed using a nonparametric one-way ANOVA followed by
LSD’s multiple comparison post test (for Table 2). Comparison of
PI and protective rate was performed using x
2 analysis. The
analyses were done by using SPSS version 17.0 for Windows
(SPSS, Chicago, IL, USA). P values less than 0.05 were considered
statistically significant in all cases.
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